- Datum23.10.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalterstock3
Regeneron Pharmaceuticals Inc. Chart
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenRegeneron Pharmaceuticals Inc. Realtime-Kurs
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
Nasdaq | VK | |||||
L&S | VK | |||||
Tradegate | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Regeneron Pharmaceuticals Inc.
Webinar zu Regeneron Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)769,190-1.211,200
- Jahrestief / Hoch ($)871,390-1.211,200
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Regeneron Pharmaceuticals Inc.
Termine von Regeneron Pharmaceuticals Inc.
- Okt31Regeneron Pharmaceuticals Inc.Q3 2024 Earnings Release
- Jan31Regeneron Pharmaceuticals Inc.Q4 2024 Earnings Release
- Mai1Regeneron Pharmaceuticals Inc.Q1 2025 Earnings Release
Beschreibung
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).